News & Insights

3 min read

Global Spotlight Shines on mRNA Thanks to Pfizer, BioNTech COVID-19 Vaccine Candidate

By Debra Valsamis on 11/11/2020

In the science shot heard ‘round the world, Pfizer and BioNTech announced Monday that their vaccine candidate (aka “BNT162b2”) appears to be more than 90% effective in preventing SARS-CoV-2 among those without evidence of prior infection. And since that news broke on the same day that the number of confirmed U.S. cases of COVID-19 crossed yet another grim threshold — 10 million infected — it couldn’t have come at a better time.

Topics: Insights Covid SARS-CoV-2 COVID-19 mRNA